Literature DB >> 25436734

Effects of energy restriction on activity of the hypothalamo-pituitary-adrenal axis in obese humans and rodents: implications for diet-induced changes in body composition.

Radhika V Seimon1, Nikita Hostland, Stephanie L Silveira, Alice A Gibson, Amanda Sainsbury.   

Abstract

BACKGROUND: Obesity treatments aim to maximize fat loss, particularly abdominal or visceral fat, without compromising lean or bone mass. However, the literature contains numerous examples of obesity treatments that - in addition to fat loss - result in loss of lean mass and/or bone mass.
MATERIALS AND METHODS: Because of the known effects of energy restriction to increase activity of the hypothalamo-pitutiary adrenal (HPA) axis in lean humans and animals, and because increases in circulating glucocorticoid levels could potentially contribute to adverse body compositional changes with obesity treatments, we conducted a systematic PubMed search to determine whether HPA axis activation also occurs in response to energy restriction in obese humans and animals. RESULTS AND
CONCLUSIONS: In most studies in obese humans, short-term severe energy restriction increased circulating cortisol levels, and this response was also seen in two longer-term human studies involving severe or moderate energy restriction. These findings parallel studies on short- or long-term energy restriction in obese rodents, with most studies showing increases in circulating corticosterone concentrations, and no change or actual increases in hypothalamic expression of corticotropin-releasing hormone, urocortin 3 or their receptors. However, a significant proportion of studies involving longer-term severe or moderate energy restriction in obese humans showed no change or decreases in HPA axis function. There was variability among human studies in the duration of energy restriction and timing of the HPA axis investigations (i.e., during energy restriction, or after a period of post-restriction weight maintenance). In order to unambiguously determine changes in HPA axis function with energy restriction in obese humans, it will be important to assess HPA axis function at multiple time points during energy restriction, given that obese individuals may spend many weeks or months in severe or moderate energy restriction in order to reduce excess weight, and given that increases in glucocorticoid function can have significant effects on body composition within weeks to months.

Entities:  

Mesh:

Year:  2013        PMID: 25436734     DOI: 10.1515/hmbci-2013-0038

Source DB:  PubMed          Journal:  Horm Mol Biol Clin Investig        ISSN: 1868-1883


  5 in total

Review 1.  Bundling the haystack to find the needle: Challenges and opportunities in modeling risk and resilience following early life stress.

Authors:  Heather C Brenhouse; Kevin G Bath
Journal:  Front Neuroendocrinol       Date:  2019-06-05       Impact factor: 8.606

2.  The Nutrient and Energy Sensor Sirt1 Regulates the Hypothalamic-Pituitary-Adrenal (HPA) Axis by Altering the Production of the Prohormone Convertase 2 (PC2) Essential in the Maturation of Corticotropin-releasing Hormone (CRH) from Its Prohormone in Male Rats.

Authors:  Anika M Toorie; Nicole E Cyr; Jennifer S Steger; Ross Beckman; George Farah; Eduardo A Nillni
Journal:  J Biol Chem       Date:  2016-01-11       Impact factor: 5.157

3.  Late-Onset Calorie Restriction Improves Lipid Metabolism and Aggravates Inflammation in the Liver of Old Wistar Rats.

Authors:  Ana Teofilović; Miloš Vratarić; Nataša Veličković; Danijela Vojnović Milutinović; Aleksandra Mladenovic; Milica Prvulovic; Ana Djordjevic
Journal:  Front Nutr       Date:  2022-05-23

Review 4.  Energetic stress: The reciprocal relationship between energy availability and the stress response.

Authors:  C S Harrell; C F Gillespie; G N Neigh
Journal:  Physiol Behav       Date:  2015-10-09

Review 5.  New Insights into the Role of Insulin and Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Metabolic Syndrome.

Authors:  Joseph A M J L Janssen
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.